





EB-1A RFE Risk Assessment Report

Date: 2025-07-28 16:59

Table of Contents

-  Risk Matrix
-  Rule-Based Findings
-  Repetitive Letters
-  Recommendations

Risk Matrix

Criterion	Risk Level	Issues Detected
Criterion 1	High	4
Criterion 5	High	5
Criterion 3	High	5
Criterion 4	High	4
Criterion 6	High	4
Criterion 3	High	4
Criterion 6	High	4

Rule-Based Findings

Criterion 1

Dr. Mehta received the "Global BioInnovation Award 2022" for his advances in synthetic biology. The award is competitive and internationally recognized in the biotech industry.

- Missing expected detail: award name
- Missing expected detail: competition
- Missing expected detail: selection
- Missing expected detail: number of recipients

Criterion 5

Dr. Mehta received the "Global BioInnovation Award 2022" for his advances in synthetic biology. The award is competitive and internationally recognized in the biotech industry.

- Missing expected detail: citation count
- Missing expected detail: h-index
- Missing expected detail: patent
- Missing expected detail: letter of impact
- Missing expected detail: commercial use

Criterion 3

Dr. Mehta designed a novel CRISPR-based platform to treat rare autoimmune diseases. This work has been cited in over 2,000 peer-reviewed articles in genetic therapy journals.

- Missing expected detail: publication title
- Missing expected detail: media name
- Missing expected detail: author
- Missing expected detail: date
- Missing expected detail: quote about applicant

Criterion 4

Dr. Mehta designed a novel CRISPR-based platform to treat rare autoimmune diseases. This work has been cited in over 2,000 peer-reviewed articles in genetic therapy journals.

- Missing expected detail: journal name
- Missing expected detail: review confirmation
- Missing expected detail: conference name
- Missing expected detail: dissertation

Criterion 6

Dr. Mehta designed a novel CRISPR-based platform to treat rare autoimmune diseases. This work has been cited in over 2,000 peer-reviewed articles in genetic therapy journals.

- Missing expected detail: journal name
- Missing expected detail: impact factor
- Missing expected detail: peer-reviewed
- Missing expected detail: conference name

Criterion 3

He is the author of 12 articles in top-tier journals such as Nature Biotechnology and Genome Research.

- Missing expected detail: publication title
- Missing expected detail: media name
- Missing expected detail: date
- Missing expected detail: quote about applicant

Criterion 6

He is the author of 12 articles in top-tier journals such as Nature Biotechnology and Genome Research.

- Missing expected detail: journal name
- Missing expected detail: impact factor
- Missing expected detail: peer-reviewed
- Missing expected detail: conference name

Repetitive Recommendation Letters

No significant repetition detected.

Editable Recommendations

Fix for Criterion 1:

"Consider rephrasing the excerpt to explicitly state the impact, significance, or national/international recognition."

Fix for Criterion 5:

"Consider rephrasing the excerpt to explicitly state the impact, significance, or national/international recognition."

Fix for Criterion 3:

"Consider rephrasing the excerpt to explicitly state the impact, significance, or national/international recognition."

Fix for Criterion 4:

"Consider rephrasing the excerpt to explicitly state the impact, significance, or national/international recognition."

Fix for Criterion 6:

"Consider rephrasing the excerpt to explicitly state the impact, significance, or national/international recognition."

Fix for Criterion 3:

"Consider rephrasing the excerpt to explicitly state the impact, significance, or national/international recognition."

Fix for Criterion 6:

"Consider rephrasing the excerpt to explicitly state the impact, significance, or national/international recognition."